COVID-19 vaccine candidate by Pfizer, BioNTech shows more than 90% effectivity
Singapore, Nov. 10 -- Pfizer Inc. and BioNTech SE have announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.
"The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort," said Prof. Ugur Sahin, BioNTech co-founder and CEO. "When we embarked on this journey 10 months ago this is what we aspired to ac...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.